<DOC>
	<DOCNO>NCT01566695</DOCNO>
	<brief_summary>Evaluation Efficacy Safety Oral Azacitidine plus Best Supportive care versus Placebo Best Supportive care subject red blood cell ( RBC ) transfusion-dependent anemia thrombocytopenia due International Prognostic Scoring System ( IPSS ) low risk myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>The Efficacy Safety Oral Azacitidine Plus Best Supportive Care Versus Placebo Best Supportive Care Subjects With Red Blood Cell ( RBC ) Transfusion-Dependent Anemia Thrombocytopenia Due International Prognostic Scoring System ( IPSS ) Low Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>18 year old Have document diagnosis MDS Anemia require red blood cell transfusion Thrombocytopenia ( sustain least 21 day ) within 14 day prior randomization Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Must agree follow pregnancy precaution require protocol . Must willing consent two bone marrow aspirate procedure complete study . Secondary hypoplastic MDS subtype eligibility treatment immunotherapy Prior treatment azacitidine , decitabine , hypomethylating agent lenalidomide ( lenalidomide : unless last dose receive &gt; = 8 week prior inclusion study ) . Prior allogeneic autologous stem cell transplant Eligible allogenic autologous stem cell transplant History inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) , celiac disease ( ie , sprue ) , prior gastrectomy upper bowel removal , gastrointestinal disorder defect Thrombocytopenia secondary possible cause , include medication ( ) , congenital disorder ( ) , immune disorder ( ) , microvascular disorder ( ) Use cytotoxic , chemotherapeutic , targeted investigational agents/therapies , thrombopoiesisstimulating agent ( TSAs ) , erythropoiesisstimulating agent ( ESAs ) red blood cell hematopoietic growth factor , within 28 day prior randomization Ongoing medically significant adverse event previous treatment , regardless time period Concurrent use ironchelating agent , ( except subject stable decrease dose least 8 week ( 56 day ) prior randomization ) , corticosteroid ( except subject stable decrease dose ≥ 1 week prior randomization medical condition MDS ) Prior history cancer , MDS , unless subject free disease ≥ 3 year . ( Basal squamous cell carcinoma skin , carcinoma situ cervix , carcinoma situ breast , incidental histologic find prostate cancer ) ( T1a T1b use tumor , node , metastasis [ TNM ] clinical staging system allow ) Significant active cardiac disease within previous 6 month Uncontrolled systemic fungal , bacterial , viral infection Known Human Immunodeficiency Virus ( HIV ) Hepatitis C ( HCV ) infection , evidence active Hepatitis B Virus ( HBV ) infection Known clinically significant anemia due iron , vitamin B12 , folate deficiency , autoimmune hereditary hemolytic anemia , gastrointestinal bleeding Abnormal coagulation parameter Abnormal liver function test result Abnormal kidney function test result Known suspect hypersensitivity azacitidine mannitol Any significant medical condition , laboratory abnormality , psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>